NBTXR3
Phase 1Small molecule
NBTXR3 is one of 24 small molecule programs targeting Advanced Cancers. It is currently in Phase 1.
2
Indications
3
Total Trials
2
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
31 competitors in Advanced Cancers
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbApproved
Keytruda
Merck & Co.Phase 2
Taxol
TevaPhase 2
Camptosar
PfizerPhase 2
Adriamycin
PfizerPhase 2
Tecentriq
RochePhase 2
Abraxane
Bristol-Myers SquibbPhase 2
Lynparza
AstraZenecaPhase 2
Paraplatin
AAvyxa
Phase 2
Ativan
BBausch Health Americas, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Cancers1 trial
Prostate Adenocarcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NBTXR3. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- NNanobiotix